These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1567 related items for PubMed ID: 9639369

  • 21. Notice to readers: updated recommendations of the Advisory Committee on Immunization Practices (ACIP) for the control and elimination of mumps.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2006 Jun 09; 55(22):629-30. PubMed ID: 16761359
    [Abstract] [Full Text] [Related]

  • 22. Administration of measles-mumps-rubella vaccination with other childhood schedule vaccines.
    Heath TC, Burgess MA, O'Brien ED.
    Commun Dis Intell; 1998 Aug 06; 22(8):159. PubMed ID: 9735551
    [No Abstract] [Full Text] [Related]

  • 23. MMR vaccine coverage at 24 months stabilises in the UK.
    Commun Dis Rep CDR Wkly; 1999 Mar 26; 9(13):113, 116. PubMed ID: 10230112
    [No Abstract] [Full Text] [Related]

  • 24. Update: vaccine side effects, adverse reactions, contraindications, and precautions. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep; 1996 Sep 06; 45(RR-12):1-35. PubMed ID: 8801442
    [Abstract] [Full Text] [Related]

  • 25. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K, Nicoara C, Germann D, Matter L.
    Schweiz Med Wochenschr; 1998 Apr 25; 128(17):649-57. PubMed ID: 9622837
    [Abstract] [Full Text] [Related]

  • 26. Measles, mumps, and rubella: recommendations for children/adolescents.
    Nurse Pract; 1996 Oct 25; 21(10):88, 91-2, 94. PubMed ID: 8895194
    [No Abstract] [Full Text] [Related]

  • 27. Reactogenicity and immunogenicity of a new combined measles-mumps-rubella vaccine: results of a multicentre trial. The Cooperative Group for the Study of MMR vaccines.
    Crovari P, Gabutti G, Giammanco G, Dentico P, Moiraghi AR, Ponzio F, Soncini R.
    Vaccine; 2000 Jun 15; 18(25):2796-803. PubMed ID: 10812221
    [Abstract] [Full Text] [Related]

  • 28. Measles, Mumps, Rubella Vaccine (PRIORIX): Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.
    Krow-Lucal E, Marin M, Shepersky L, Bahta L, Loehr J, Dooling K.
    MMWR Morb Mortal Wkly Rep; 2022 Nov 18; 71(46):1465-1470. PubMed ID: 36395065
    [Abstract] [Full Text] [Related]

  • 29. The measles-mumps-rubella vaccination program in Finland.
    Lerman SJ.
    N Engl J Med; 1995 Apr 20; 332(16):1103. PubMed ID: 7898541
    [No Abstract] [Full Text] [Related]

  • 30. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination.
    Matter L, Germann D, Bally F, Schopfer K.
    Eur J Epidemiol; 1997 Jan 20; 13(1):61-6. PubMed ID: 9062781
    [Abstract] [Full Text] [Related]

  • 31. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
    Bae GR, Choe YJ, Go UY, Kim YI, Lee JK.
    Vaccine; 2013 May 31; 31(24):2661-6. PubMed ID: 23602654
    [Abstract] [Full Text] [Related]

  • 32. Lack of adverse reactions to measles, mumps, and rubella vaccine in egg-allergic children.
    Freigang B, Jadavji TP, Freigang DW.
    Ann Allergy; 1994 Dec 31; 73(6):486-8. PubMed ID: 7998661
    [Abstract] [Full Text] [Related]

  • 33. Retinopathy following measles, mumps, and rubella vaccination in an immuno-incompetent girl.
    Schuil J, van de Putte EM, Zwaan CM, Koole FD, Meire FM.
    Int Ophthalmol; 1998 Dec 31; 22(6):345-7. PubMed ID: 10937849
    [Abstract] [Full Text] [Related]

  • 34. Vaccination with a combined vaccine against measles, mumps and rubella aiming at elimination of the three diseases.
    Böttiger M, Christenson B, Strandell A, Romanus V.
    Dev Biol Stand; 1986 Dec 31; 65():37-43. PubMed ID: 3556776
    [Abstract] [Full Text] [Related]

  • 35. American Academy of Pediatrics. Committee on Infectious Diseases. Age for routine administration of the second dose of measles-mumps-rubella vaccine.
    American Academy of Pediatrics. Committee on Infectious Diseases.
    Pediatrics; 1998 Jan 31; 101(1 Pt 1):129-33. PubMed ID: 11345975
    [Abstract] [Full Text] [Related]

  • 36. Measles, mumps, rubella vaccine administration in egg-sensitive children: systemic reactions during vaccine desensitization.
    Trotter AC, Stone BD, Laszlo DJ, Georgitis JW.
    Ann Allergy; 1994 Jan 31; 72(1):25-8. PubMed ID: 8291745
    [Abstract] [Full Text] [Related]

  • 37. The MMR vaccine debate.
    Community Nurse; 1998 Oct 31; 4(9):12-3. PubMed ID: 10326363
    [No Abstract] [Full Text] [Related]

  • 38. Recommended childhood immunization schedule--United States, 1998.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 1998 Jan 16; 47(1):8-12. PubMed ID: 9450723
    [Abstract] [Full Text] [Related]

  • 39. [Economic evaluation on different two-dose-vaccination-strategies related to Measles, Mumps and Rubella Combined Attenuated Live Vaccine].
    He HQ, Zhang B, Yan R, Li Q, Fu J, Tang XW, Zhou Y, Deng X, Xie SY.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Aug 10; 37(8):1121-6. PubMed ID: 27539345
    [Abstract] [Full Text] [Related]

  • 40. A benefit-cost analysis of two-dose measles immunization in Canada.
    Pelletier L, Chung P, Duclos P, Manga P, Scott J.
    Vaccine; 1998 Aug 10; 16(9-10):989-96. PubMed ID: 9682349
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 79.